MultiplAI Health, a London, UK-based diagnostics company developing universal precision screening technology for cardiovascular and other complex diseases, raised $2.7 million in seed funding.
The round led by SF500, Zentynel, and Time Partners, is being directed towards achieving technical validation of their proprietary RNA-based, AI-driven product, building a MultiplAI team, and expanding its operations and partnership in the US.
MultiplAI Health is combining genomic data and artificial intelligence to develop a simple, accessible whole blood test - known as a liquid biopsy - that gives a highly accurate assessment of an individual's risk of cardiovascular and other complex diseases at a fraction of the cost of today’s screening options.
The universal test will enable healthcare professionals to identify cardiovascular risks before symptoms start to appear and enables people to progressively track and manage their CVD risk from an early age.
MultiplAI Health launched in the UK in 2020, with the support of the startup creation engine Illumina Accelerator Cambridge run by genomic sequencing specialists Illumina.
Since then, the company has launched several clinical studies in the UK and Argentina and is now opening operations in the United States, a country where almost half (48%) of all adults have some form of cardiovascular disease.
MultiplAI Health is eyeing opportunities with its liquid biopsy to enter the global screening market, valued at US $211 billion in 2021 and estimated to more than double within the next five years.
Company: MultiplAI Health Ltd
Raised: $2.7M
Round: Seed Round
Funding Month: March 2023
Lead Investors: SF500, Zentynel, and Time Partners
Additional Investors:
Company Website: https://www.multiplaihealth.com/
Software Category: Genomic Screening
About the Company: Founded by Charlie Luzzani, Mark Ramondt, and Santiago Miruka, MultiplAI Health is a biotech diagnostics company developing screening technology to transform how cardiovascular diseases are diagnosed. The company offers a whole blood screening test using RNA sequencing and artificial Intelligence to detect complex diseases, including cardiovascular disorders and cancer. MultiplAI Health uses artificial intelligence and genomic data to create a liquid biopsy that will be affordable and easy to use. The company is based in London, UK, with clinical and lab operations in Cambridge, UK, and Buenos Aires, Argentina.
Source: MultiplAI Health-Press Release